Although some biologic therapies antagonizing FOXO1 activity were reported in treating cancers, wound repair, and cardiovascular diseases [53,54,55,56,57], many efforts are still focused on designing small-molecule compounds indicated for treating metabolic disorders [58]. The gene discussed is FOXO1; the disease is cancer.